Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000303836 | SCV000345907 | likely benign | not specified | 2016-09-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000886965 | SCV001030496 | likely benign | not provided | 2025-01-06 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000886965 | SCV001148801 | likely benign | not provided | 2024-11-01 | criteria provided, single submitter | clinical testing | NR1H4: PP3, BS2 |
Breakthrough Genomics, |
RCV000886965 | SCV005218216 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003920174 | SCV004728930 | uncertain significance | NR1H4-related disorder | 2024-04-17 | no assertion criteria provided | clinical testing | The NR1H4 c.518T>C variant is predicted to result in the amino acid substitution p.Met173Thr. This variant has been reported to be associated with intrahepatic cholestasis of pregnancy (Van Mil et al. 2007. PubMed ID: 17681172). This variant is reported in 0.64% of alleles in individuals of European (Non-Finnish) descent in gnomAD including two homozygotes of unknown phenotype, which might be too common to be a highly penetrant cause of disease. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |